CD274 and non-small cell lung carcinoma: For instance, programmed death receptor (PD-1)/PD-L1 interaction is recognized as a key mechanism of immune evasion in NSCLC, and ICIs such as nivolumab are used to treat tumors that express PD-L1 [12].